After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...

Biomarker testing also extends beyond cancer care. The science is being used in the treatment of other diseases including ...

The U.S. Food and Drug Administration approved treatment for 11 patients with the rare familial ALS caused by mutations in ...

The first study participant was enrolled in July 2024, and since that time, the consortium has recruited over 300 participants.

Recent research shows that only 5% to 10% of patients have a family member diagnosed with the disease, and there are only a handful of known genetic mutations. So, what's causing the other 90% of ...

SNUG01 is a first-in-class targeted gene therapy that’s designed to increase the levels of TRIM72, a protein with ...

Q4 2024 Earnings Call Transcript March 31, 2025 Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations.

After losing her husband to ALS, Indu Navar used her tech background to create real change. Learn how she built a data-driven ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s ...